Phase 3 N=17,183 Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Time to All-Cause Mortality — 440; 423; 439 Number of deaths
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=480 Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Sexual Dysfunctions, Psychological
Primary: Frequency of Adverse Events — 331; 206; 58; 51 participants with any adverse event
Phase 3 N=52 Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
HIV Infection · Cardiovascular Disease · Inflammation
Primary: Percent Change in FMD — 0.57; -0.05 percent change in FMD — p=0.17
Phase 3 N=693 Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Acute Otitis Externa
Primary: Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit — 71.7; 33.3 percentage of participants
Phase 3 N=304 Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD
PTSD · Sleep Disorders
Primary: CAPS Recurrent Distressing Dreams Item — -1.9; -1.7 scores on a scale
Phase 3 N=652 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Phase 3 N=26,449 Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)
Atherosclerosis · Ischemia · Myocardial Infarction
Primary: Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary…
Phase 3 N=1,072 Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis, When Tdap is Concomitantly Administered With MenACWY-CRM Compared to Tdap Given…
Phase 3 N=267 Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain
Pain, Postoperative
Primary: Wake Time After Sleep Onset (WASO) Measured by Actigraphy — 155.25; 180.08; 364.83 Minutes — p=0.3047
Phase 3 N=642 12 / 48 wk Pivotal PFT vs PBO in COPD II
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks) — 0.008; 0.159; 0.152 Liter — p=<0.0001
Phase 3 N=21 Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes
Type 2 Diabetes
Primary: Total Norm AUC Average by Group (Normalized) — 150.8; 175.9; 149.9; 175.1 mg/(dL/hr) normalized
Phase 3 N=1,144 Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
Breast Cancer
Primary: Progression-Free Survival (PFS) — 9.5; 8.2 months — p=0.077
Phase 3 N=12 Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) on Norethisterone of NPC-01 — 69.183 ng･hr/mL
Phase 3 N=1,160 Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Number of Patients With Drug Related Adverse Events — 19; 25; 13; 13 participants
Phase 3 N=600 Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery
Elevated Cardiac Risk · Coronary Arteries Disease Risk
Primary: Number of Participants With Myocardial Necrosis (MN) — 57; 54 participants — p=0.0052